IniB, iniA and iniC genes of mycobacteria and methods of use

Details IniB, iniA and iniC genes of mycobacteria and methods of use IniB, iniA and iniC genes of mycobacteria and methods of use

2001-07-31

2004-11-23

Swartz, Rodney P (Department: 1645)

Chemistry: molecular biology and microbiology

Micro-organism, per se ; compositions thereof; proces of...

Bacteria or actinomycetales; media therefor

C424S168100, C424S248100, C435S320100, C435S863000, C435S864000, C435S865000, C435S866000, C536S023100, C536S023700, C536S024320

Reexamination Certificate

active

06821769

ABSTRACT:

BACKGROUND OF THE INVENTION
This invention is based upon the discovery by the inventors of the iniB, inia and iniC genes, and the proteins encoded by these genes which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, isoniazid (INH) and ethambutol (EMB). The discovery of the iniB, inia and iniC genes, and the proteins encoded by these genes will have important implications in the identification of drugs effective against
M. tuberculosis
, as well as the treatment of drug-resistant mycobacterial strains.
Many highly effective classes of antibiotics work by inhibiting microbial cell wall biosynthesis. In
M. tuberculosis
several antibiotics, including isoniazid and ethambutol, appear to act by this general mechanism.
EMB is a selective antimycobacterial drug recommended for clinical use in 1996 (Karlson, A. G., Am Rev Resp Dis 84, 905-906 (1961)). Today, EMB remains an important component of tuberculosis treatment programs. Unfortunately, resistance to ethambutol has been described in 2-4% of clinical isolates of
M. tuberculosis
in the USA and other countries, and is prevalent among isolates from patients with multidrug-resistant tuberculosis (Bloch, AB., Cauthen, GM., Onorato, IM., et al. Nationwide survey of drug-resistant tuberculosis in the United States.
JAMA
271, 665-671 (1994)).
EMB targets the mycobacterial cell wall, a unique structure among prokaryotes which consists of an outer layer of mycolic acids covalently bound to peptidoglycan via the arabinogalactan (Besra, G. S. & Chatterjee, D. in
Tuberculosis. Pathogenesis, protection, and control
(ed Bloom, B. R.) 285-306 (ASM Press, Washington D.C., 1994)). Lipoarabinomannan, another cell wall component of significant biological importance, shares with arabinogalactan the overall structure of the arabinan polymer (Chatterjee, D., et al.,
J. Biol Chem
266, 9652-9660 (1991)).
EMB inhibits the in vivo conversion of [
14
C]glucose into cell wall arabinan (Takayama, K. & Kolburn, J. O.,
Antimicrob Agents Chemother
33, 143-1499 (1989)), and results in the accumulation of the lipid carrier decaprenyl-P-arabinose (Wolucka, B. A., et al., J Biol Chem 269, 23328-23335 (1994)), which suggest that the drug interferes with the transfer of arabinose to the cell wall acceptor. The synthesis of lipoarabinomannan is also inhibited in the presence of EMB (Deng, L., et al.
Antimicrob Agents Chemother
39, 694-701 (1995)), (Mikusova, K., et al., Antimicrob Agents Chemother 39, 2484-2489 (1995)); again, this indicates a specific effect on arabinan biosynthesis.
Isoniazid (INH) is a front-line drug in the treatment of tuberculosis. INH is a prodrug that requires activation by the catalase-peroxidase enzyme (katG) to an active form (Zhang et al., (1992) Nature 358, 591-593). It is likely that INH acts by blocking mycolic acid biosynthesis as evidenced by the physical and biochemical changes that occur at the same time as INH toxicity (Winder and Collins, (1970) J. Gen. Microbiol. 63, 41; Davidson and Takayama, (1979) Antibicrob. Agents Chemother. 16, 104). Treatment with INH leads to the accumulation of saturated hexacosanoic acid, and has been shown to inhibit the action of several enzymes thought to be involved in mycolic acid biosynthesis including InhA (Banedjee et al., (1994) Science 263, 227-230) and kasA (Mdluli et al., (1998) Science 280, 1607-1610).
Recent reports have documented a significant increase in the global incidence of drug resistant tuberculosis. Thus, there is a need for the identification and characterization of new target genes and proteins to aid in screening for new drugs. This would require the identification of genes that participate in the biosynthesis of the mycobacterial cell wall and the identification of mutants of these genes encoding proteins that confer resistance to drugs. While it is possible that the iniB, iniA, and iniC gene products are not in themselves targets for currently available antibiotics, these proteins may act to protect
M. tuberculosis
and other mycobacteria from toxic effects that occur when cell wall biosynthesis is inhibited by antibiotics. Novel drugs that inhibit the iniB, iniA, and iniC proteins may therefore act synergistically with other cell wall active antibiotics and prove useful in treating tuberculosis, including drug resistant tuberculosis.
Current high throughput drug screens do not usually assay agents at high concentrations because nonspecific toxic effects are common. This strategy may miss important compounds that could be modified to have higher potency. This is a particular concern for screening compounds against
M. tuberculosis
because many drugs may have difficulty penetrating through its lipid laden cell wall. Thus, there is a great need for new drug screens which overcome the deficiencies of the present screens for compounds against
M. tuberculosis.
SUMMARY OF THE INVENTION
The present invention is directed to the nucleic acid sequences of the iniB, iniA and iniC genes, and the proteins encoded by these genes which are induced by a broad class of antibiotics that act by inhibiting cell wall biosynthesis, including the first line antituberculosis agents, ethambutol (EMB) and isoniazid. The present invention further provides for the identification, isolation and characterization of these nucleic acid sequences and the proteins which they encode.
The present invention specifically provides purified and isolated nucleic acid sequences of the iniB, iniA, and iniC genes, as well as mutated forms of these genes. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the nucleic acid sequences of the iniB, iniA, and iniC genes, as well as mutated forms of these genes, and mixtures thereof, which may be formulated in kits, and used in the detection of drug resistant mycobacterial strains.
The present invention also provides purified active iniB, iniA, and iniC proteins encoded by the iniB, iniA, and iniC genes. Also provided are antibodies immunoreactive with the protein(s) expressed by the iniB, iniA, and iniC genes, and analogues thereof, as well as antibodies immunoreactive with the protein(s) expressed by the these genes.
Further provided by the present invention is a method of screening drugs or compounds to determine whether the drug or compound is effective against
Mycobacterium tuberculosis.
Additional objects of the invention will be apparent from the description which follows.


REFERENCES:
Altschul et al., Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids REs., 25:3389-3402, 1997.
Bairoch et al., The Prosite database, its status in 1997. Nucleic Acids Res., 25:217-221, 1997.
Banerjee et al., inhA, a gene encoding a target for isoniazid and ethionamide inMycobacterium tubreculosis. Science, 263:227-230, 1994.
Cole et al., Deciphering the biology ofMycobacterium tuberculosisfrom the complete genome sequence, Nature, 393:537-544, 1998.
de Saizieu et al., Bacterial transcript imaging by hybridization of total RNA to olignucleotide arrays. Nature Biotech., 16:45-48, 1998.
Garbe et al., Isoniazid induced expression of the antigen 85 complex in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 40:1754-1756, 1996.
Kinger and Tyagi, Identification and Cloning of genes differentially expressed in the virulent strain ofMycobacterium tuberculosis. Gene, 131:113-117, 1993.
Mathiopoulos and Sonenshein, Identification of Bacillus subtilis expressed early during sporulation. Mol. Microbiol., 3:1071-1081, 1989.
Mdluli et al., Inhibition of aMycobacterium tuberculosisbeta-ketoacyl ACP synthase by isoniazid. Science, 280:1607-1610, 1998.
Plum and Clark-Cutiss, Induction ofMycobacterium aviumgene expression following phagocytosis by human macrophages. Infect. and Immun. 62:476-483, 1994.
Wong and McClelland, Stress-inducible gene of salmonella typhimurium identified by arbitrarily primed PCR of RNA. Proc. Natl. Acad. Sci. USA, 91:639-643, 1994

Affiliated with

Also associated with

Rating

IniB, iniA and iniC genes of mycobacteria and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IniB, iniA and iniC genes of mycobacteria and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IniB, iniA and iniC genes of mycobacteria and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3296736